New treatment approved by FDA.
Medscape (4/28, Mulcahy) reported, "The US Food and Drug Administration (FDA) has approved abiraterone acetate (Zytiga, Cougar Biotechnology) in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer in men who have received prior docetaxel chemotherapy."
Bloomberg News (4/29, Waters, Nussbaum) reports that the drug "targets a protein to reduce levels of testosterone, a male hormone that fuels prostate cancer growth," the FDA said in a statement.
WebMD (4/28, Hendrick) reports that the FDA "says the drug's safety and effectiveness were established in a clinical study involving 1,195 patients with late-stage castration-resistant prostate cancer who had received treatment with docetaxel chemotherapy." Patients in the study who received abiraterone acetate "and prednisone combo had a median overall survival of 14.8 months, compared to 10.9 months for those in the group taking the placebo-prednisone combination." Reuters (4/29, Berkrot) and Dow Jones Newswire (4/29, Dooren, Subscription Publication) also cover the story.
52 at Dx (3/12/10), father died of PCa
PSA: 10/16/09 - 2.8; 1/11/10 - 3.8; since RALP - <0.1
RALP 5/19/10, Dr. Lee, U. Penn Presby
Gleason 6, gland involvement < 2%; tumor in peripheral zone both sides; no capsular, extracapsular extension, lymph node, or seminal vesical involvement; no positive margins
Incontinence: no pads except at karate
ED: pump. Levitra 10mg every other night